Next-generation Sequencing Informatics Market Size & Share, by Product (Sequencing Platforms, Consumables, Software & Services); Application; End user; Workflow; Delivery Mode - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2025-2034

Next-generation Sequencing Informatics Market - Regional Analysis

North America Market Insights

North America in the next-generation sequencing informatics industry is considered the dominant region, with an expected highest share of 45.1% by the end of 2034. The market’s growth in the region is highly fueled by effective government-based funding as well as the presence of strong healthcare facilities. Additionally, the NIH’s USD 5.5 billion yearly provision for genomic research budget and Medicare’s expansion for NGS coverage, currently reimbursing at least 80% of oncology tests, are also suitable for uplifting the market in the region. Besides, liquid biopsy integration and AI-based NGS platforms are other notable trends that are positively impacting the market in the overall region.

The next-generation sequencing informatics sector in the U.S. is significantly growing, accounting for almost 95% of the region’s market, attributed to the All of Us Program initiated by the NIH, along with the USD 1.3 billion expenditure through Medicaid NGS. Besides, the FDA has successfully approved 17 AI-NGS tools as of 2023, diminishing analysis expenses by 42%. Meanwhile, Medicare effectively covers FoundationOne CDx, but state-based Medicaid barriers leave an estimated 16 million underserved patients. The AHRQ data has revealed that NGS reduces cancer expenses by USD 3.9 billion through early detection, thus denoting a positive impact on the market in the country.

The next-generation sequencing informatics market in Canada is also growing at a rate of 10.5%, which is generously supported by the USD 420 million genomics 2030 strategy. Ontario is deliberately leading with 200,150 NGS-based patients, but PHAC has reported that almost 35% of oncologists are devoid of training. Besides, Health Canada has rapidly approved 12 NGS panels in 2023, even though import expenses remain 35% above U.S. levels. Meanwhile, BC Cancer Agency’s NGS program has diminished the wait timeline by 60%, thereby suitable for market;s development in the country.

North America's NGS Informatics Trade & Supply Chain Facilities (2022–2025) 

APAC Market Insights

Asia Pacific in the next-generation sequencing informatics market is considered the fastest-growing region, with a share of 20.3% and a growth rate of 15.2% between 2025 and 2034, which is highly attributed to government-based precision medicine, along with increasing cancer prevalence initiatives. China is dominating the region, driven by NMPA’s acceptance of more than 19 NGS panels and USD 2.5 billion yearly genomics funding. This is effectively followed by a surge in India, which is backed by administrative policies since 2024. Besides, South Korea is also leading in the AI-NGS incorporation, with almost 82% of tertiary hospitals utilizing AI-powered variant callers, thus suitable for the market growth.

The market in China is projected to garner at least 46% of the region’s share by the end of 2034, which is effectively fueled by fast clinical implementation and strong government support. The NMPA has accepted over 22 NGS panels as of 2023, which include BGI’s MGISEQ-2000 for oncology. Besides, domestically funded genomics programs have allocated USD 2.2 billion every year by targeting 13 million sequenced genomes by the end of 2030. However, localized data laws have raised compliance expenses by an estimated 32.5%, and at least 75% of sequencers are imported from Germany and the U.S., developing vulnerabilities in the supply chain.

The next-generation sequencing informatics market in India is increasing with an 18.5% growth rate, attributed to Ayushman Bharat’s 2024 coverage extension for almost 500,200 patients. As per an article published by the ICMR, it has been reported that 2.6 million patients are NGS-eligible every year, but only 90% are unable to gain accessibility, owing to high expenses, amounting to approximately ₹50,500 per test. Besides, the 2023 National Biopharma Mission made an investment of USD 260 million in localized NGS production to diminish reagent import reliance by 22%. Meanwhile, Tata Medical Center’s AI-NGS program reduced turnaround duration by 45%, thus suitable for market upliftment in the country.

APAC Government Investments/Policies in NGS Informatics (2022–2025)

Sources: Australian Government, Services Australia, Bioeconomy Corp, Ministry of Health MY, MSIT Korea, Korea Health Industry

Europe Market Insights

Europe in the next-generation sequencing informatics market is expected to hold a considerable share of 28.2% by the end of the forecast duration, along with a 10.7% growth rate. The market’s upliftment in the region is highly fueled by an upsurge in the cancer occurrence, as well as Europe-based genomic strategies. The regional Health Data Space (HDS) generously allocated €2.8 billion by the end of 2027, particularly for NGS interoperability. Germany is leading with NGS expenditure as of 2024, along with an increase in the yearly demand growth. This is followed by the UK, with the availability of administrative-based Genomic Medicine Services, all of which aim to bolster the market in the region.

The market in Germany is dominating the region’s market, with a 30.5% revenue share, which is highly fueled by the €4.7 billion yearly government expenditure, along with universal NGS coverage, particularly for oncology. Besides, the German Medical Association has successfully mandated NGS for metastatic cancers, thereby bolstering the implementation rate by at least 18.5% yearly. Meanwhile, partnerships, such as Siemens Healthineers’ €1.2 billion collaboration with Illumina, have escalated the AI-NGS incorporation, thus creating an optimistic outlook for the overall market in the country.

The next-generation sequencing informatics market in the UK is expected to hold approximately 26.5% of the region’s market, which is highly driven by the NHS England’s Genomic Medicine Service, covering 80,500 tests every year. Besides, almost 9% of the NHS budget, accounting for £1.4 billion funds for NGS, with the Genome UK 2025 effectively targeting 500,100 sequenced genomes. Meanwhile, the 100,200 Genomes Project diminished chronic disorder diagnosis duration by 55%. In addition, private sector investments are also driving the market demand, but Brexit-based reagent delays have enhanced costs by 25%, thereby suitable for market upliftment.